AZD6244 falls short in Ph II skin cancer study.
Publication Date: 07-JAN-08
Publication Title: Pharma Marketletter
Format: Online
Company: Schering-Plough Corp.~Product development

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

US firm Array BioPharma says that its candidate anticancer agent AZD6244 failed to show superiority to Schering-Plough's Temodar (temozolomide) in the treatment of advanced melanoma. Array added that, as a result of the findings, its development partner AstraZeneca, which licensed the compound in 2003 (Marketletters passim), has shelved plans...



More articles from Pharma Marketletter
$25M for Bavarian Nordic on US govt contract., January 07, 2008
John Lechleiter to succeed Sidney Taurel as Lilly's CEO., January 07, 2008
lMediGene recruits Amgen exec Frank Mathias., January 07, 2008
Promotion for Barry Greene at Alnylam., January 07, 2008
France's Novagali names Mourad Amrane as vice president of medical aff..., January 07, 2008

Looking for additional articles?
Click here to search our database of over 3 million articles.